For general enquiries regarding PIP Implants, please call the Helpline on 020 7079 4399
London - 7th January 2012: Last Friday the MHRA advised that they found no evidence to support routine removal of PIP breast implants and they recommended that any patients who were concerned about their implant should seek clinical advice from their consultant surgeon.
HCA International's leadership supports the MHRA's position, and has today issued a commitment to any patients that have had PIP breast implant surgery at one of its hospitals, saying that it will provide full support to address their concerns.
HCA is working closely with its consultants and patients to ensure it finds the most appropriate solution for each individual. If any patients require clinical investigation or further surgical support, including the removal of the PIP implant due to clinical need, HCA will meet the cost incurred.
Michael Neeb, President and Chief Executive, HCA International, comments "recognise that there is a high level of concern amongst patients who have received PIP implants and we are determined to do everything in our power to address these concerns. HCA has built its name providing clinical services of the highest quality to its patients and we have a duty of care to all of them."
"The safety and well-being of HCA patients remains our highest priority."
For media enquiries please contact Sarah Lie on +447946 354978, Giles Fraser on +447881 623123 or Neil Huband on +447808 298 989.
HCA International Limited owns the Capital's six leading private hospitals all based in central London and each with an international reputation for the highest standards of acute and tertiary care. They are: The Wellington Hospital - the largest private hospital in Europe, London Bridge Hospital, The Harley Street Clinic, The Portland Hospital for Women and Children, The Lister Hospital and The Princess Grace Hospital.
HCA also has ten outpatient and diagnostic centres in and around London, a blood and bone cancer treatment joint venture with the NHS at University College Hospital together with a young person's cancer unit, The London Gamma Knife Centre, another joint venture with the NHS at St Bartholomew's Hospital and Harley Street at Queen's, a private patient cancer centre at the NHS Queen's Hospital in Romford. In addition, HCA is developing, with the internationally renowned Christie cancer hospital in Manchester, a new state of the art private patient unit - to be called The Christie Clinic - for cancer patients from across the North of England.
The six HCA hospitals in London treat around 300,000 patients per year. They also specialise in the most complex medical procedures including cardiac care, liver transplantation, inter cranial surgery and complex cancer care. The HCA cancer network, for example, is the largest provider of cancer care in the UK outside the NHS. Uniquely, HCA has its own clinical trials unit based in Harley Street in central London. Medical teams in HCA are involved in research programmes aimed at finding new treatments in areas such as heart disease and cancer.
In recent years HCA has invested over £300 million in capital expenditure including new diagnostic and treatment technology. As an example, HCA installed at The Harley Street Clinic, the UK's first revolutionary CyberKnife robotic radiotherapy machine, which is able to target previously untreatable tumours.